Skip to main content
TipRanks
Go Ultimate75% OFF

Zelira Therapeutics (ZLDAF) Ratios

16 Followers

Zelira Therapeutics Ratios

ZLDAF's free cash flow for Q4 2025 was AU$-2.27M. For the 2025 fiscal year, ZLDAF's free cash flow was increased by AU$0.00 and operating cash flow was AU$-2.27M. See a summary of the company’s cash flow.

Financial ratios
RatiosJun 25Jun 24Jun 23Jun 22Jun 21
Liquidity Ratios
Current Ratio0.110.600.943.125.66
Quick Ratio0.020.420.131.924.86
Cash Ratio0.000.080.081.694.62
Solvency Ratio-0.60-3.86-2.31-5.65-5.26
Operating Cash Flow Ratio-0.88-0.62-3.85-5.80-8.01
Short-Term Operating Cash Flow Coverage-2.47-1.24-50.86-80.78-95.18
Net Current Asset ValueAU$ -4.98MAU$ -5.10MAU$ -407.97KAU$ 3.07MAU$ 4.55M
Leverage Ratios
Debt-to-Assets Ratio1.651.150.010.010.01
Debt-to-Equity Ratio-0.48-1.320.010.010.01
Debt-to-Capital Ratio-0.924.150.010.010.01
Long-Term Debt-to-Capital Ratio0.00-0.880.000.000.00
Financial Leverage Ratio-0.29-1.151.071.071.04
Debt Service Coverage Ratio-1.21-8.30-25.76-69.02-60.32
Interest Coverage Ratio-9.71-8.03-96.70-249.13-226.43
Debt to Market Cap0.391.550.010.020.00
Interest Debt Per Share0.220.590.050.070.09
Net Debt to EBITDA-0.53-0.15-0.040.170.47
Profitability Margins
Gross Profit Margin-122400.15%10.83%-1068.03%-371.02%-5.90%
EBIT Margin-658713.11%-38883.04%-2435.85%-886.13%-1490.21%
EBITDA Margin-617481.55%-38378.53%-2254.79%-847.93%-1418.71%
Operating Profit Margin-602467.84%-6253.93%-2461.74%-870.75%-1455.13%
Pretax Profit Margin-586840.24%-38692.98%-2461.31%-889.62%-1496.64%
Net Profit Margin-553029.27%-38513.04%-1850.75%-775.35%-1288.84%
Continuous Operations Profit Margin-411111.74%-38692.98%-2081.80%-805.75%-1288.84%
Net Income Per EBT94.24%99.53%75.19%87.16%86.12%
EBT Per EBIT97.41%618.70%99.98%102.17%102.85%
Return on Assets (ROA)-278.92%-705.50%-16.44%-31.68%-21.72%
Return on Equity (ROE)81.33%809.96%-17.52%-33.93%-22.60%
Return on Capital Employed (ROCE)92.12%310.89%-23.16%-37.19%-25.21%
Return on Invested Capital (ROIC)128.84%-326.00%-19.42%-33.46%-21.61%
Return on Tangible Assets-465.08%-807.46%19.61%48.25%36.77%
Earnings Yield-71.80%-1001.63%-37.65%-157.05%-17.56%
Efficiency Ratios
Receivables Turnover0.140.04-275.756.0111.55
Payables Turnover0.230.022.024.810.71
Inventory Turnover1.680.072.303.710.81
Fixed Asset Turnover0.010.420.581.820.54
Asset Turnover0.000.020.010.040.02
Working Capital Turnover Ratio-0.00-0.060.180.360.21
Cash Conversion Cycle1258.11-404.32-23.4383.25-29.39
Days of Sales Outstanding2607.868886.40-1.3260.7631.60
Days of Inventory Outstanding217.075398.66158.5798.44450.79
Days of Payables Outstanding1566.8214689.37180.6875.95511.79
Operating Cycle2824.9314285.05157.25159.20482.39
Cash Flow Ratios
Operating Cash Flow Per Share-0.43-0.39-0.72-1.17-1.30
Free Cash Flow Per Share-0.43-0.39-0.72-1.17-1.30
Dividend Paid and CapEx Coverage Ratio-1226713.500.000.00-2356806.00-2154148.50
Capital Expenditure Coverage Ratio-1226713.500.000.00-2356806.00-2154148.50
Operating Cash Flow Coverage Ratio-2.29-0.74-16.55-18.82-15.64
Operating Cash Flow to Sales Ratio-7479.96-46.22-24.07-6.12-12.99
Free Cash Flow Yield-97.12%-120.20%-48.98%-123.94%-17.70%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-1.38-0.10-2.66-0.64-5.69
Price-to-Sales (P/S) Ratio7702.1138.4549.154.9473.40
Price-to-Book (P/B) Ratio-1.13-0.810.470.221.29
Price-to-Free Cash Flow (P/FCF) Ratio-1.03-0.83-2.04-0.81-5.65
Price-to-Operating Cash Flow Ratio-1.03-0.83-2.04-0.81-5.65
Price-to-Earnings Growth (PEG) Ratio0.02-0.000.04-0.040.52
Enterprise Value Multiple-1.77-0.25-2.22-0.41-4.70
Enterprise Value7.19M9.01M15.09M5.36M44.27M
EV to EBITDA-1.77-0.25-2.22-0.41-4.70
EV to Sales10957.8794.9350.123.4866.73
EV to Free Cash Flow-1.46-2.05-2.08-0.57-5.14
EV to Operating Cash Flow-1.46-2.05-2.08-0.57-5.14
Tangible Book Value Per Share-0.42-0.43-3.04-3.33-3.74
Shareholders’ Equity Per Share-0.39-0.403.164.385.70
Tax and Other Ratios
Effective Tax Rate0.300.030.150.090.14
Revenue Per Share0.000.010.030.190.10
Net Income Per Share-0.32-3.22-0.55-1.49-1.29
Tax Burden0.941.000.750.870.86
Interest Burden0.891.001.011.001.00
Research & Development to Revenue4061.8929.604.440.913.14
SG&A to Revenue738.7814.0810.173.956.77
Stock-Based Compensation to Revenue-1810.070.381.341.751.97
Income Quality1.350.121.300.791.01

Currency in AUD